There are limited published data on this strategy in VWD patients4and this study is, to the best of our knowledge, the first long-term study to examine real-life clinical use of a VWF/FVIII concentrate in prophylaxis. This evidence concerns the gene VWF and von Willebrand disease (hereditary or acquired).